<i>MTAP</i> loss in penile squamous cell carcinoma (penSCC): A genomic landscape study.
Eyal Kord(SUNY Upstate Medical University), Philippe Edouard Spiess(Moffitt Cancer Center), A. Kamat(The University of Texas MD Anderson Cancer Center), R. Graf(Foundation Medicine (United States)), Douglas I. Lin(Boston Foundation), Ole Gjoerup(Foundation Medicine (United States)), Sumanta Kumar Pal(City of Hope), Hanan Goldberg(SUNY Upstate Medical University), Shilpa Gupta(Cleveland Clinic), J L Lortat Jacob(SUNY Upstate Medical University), Andrea Necchi(Vita-Salute San Raffaele University), Petros Grivas(University of Washington), Roger Li(Moffitt Cancer Center), Dean C. Pavlick(Foundation Medicine (United States)), Liang Cheng(Brown University), Neeraj Agarwal(University of Utah), Gennady Bratslavsky(SUNY Upstate Medical University), Jeffrey S. Ross(PHG Foundation), Alina Basnet(Cancer Clinic)
Cited by 0
Related Papers
Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis
|Oncotarget|2018|15
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1